Could CBD oil lift the fog of Treatment-Resistant depression?

NCT ID NCT07696871

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether a full-spectrum cannabidiol (CBD) oil, taken under the tongue for 12 weeks, can reduce symptoms of major depressive disorder in adults who haven't improved with standard antidepressants. 120 participants will receive either the CBD oil or a placebo, while continuing their usual medication. Researchers will measure changes in depression, anxiety, sleep, and stress, and also look at blood markers of inflammation and stress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Full-spectrum cannabidiol (CBD) oil with trace THC
What this could lead to
If it works, this could offer a new option for people with depression that hasn't responded to standard treatments.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. CBD can cause side effects like drowsiness or digestive issues, and the trace THC may have mild psychoactive effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder mood disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Universidade do Sul de Santa Catarina - UNISUL

    RECRUITING

    Tubarão, Santa Catarina, 88704900, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.